---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-053303"
form_type: "8-K/A"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-04-11T23:59:59+00:00"
generated_at: "2026-05-23T16:28:01.019407+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Neumora revises stock option repricing to use closing price on May 28, 2025 annual meeting date

## Summary
- Originally repriced using Feb 13, 2025 closing price; revised on Apr 7, 2025 to use closing price on scheduled annual meeting date (May 28, 2025).
- Repricing applies to eligible options held by board, named executive officers, and other service providers under 2023 and 2020 equity plans.
- Reduced exercise price requires stockholder approval; options must be exercised on/after Aug 13, 2026 while service continues.
- Except for the closing price date, all other terms of repriced options remain unchanged.
- Annual stockholder meeting scheduled for May 28, 2025.

## SEC filing metadata
- accession: 0000950170-25-053303
- form_type: 8-K/A
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-04-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000095017025053303/0000950170-25-053303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000095017025053303/nmra-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-053303
- JSON: https://secwatch.observer/filing/0000950170-25-053303.json
- Plain text: https://secwatch.observer/filing/0000950170-25-053303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.